Post on 14-Aug-2021
www.wjpps.com Vol 7, Issue 11, 2018.
1151
Shaha et al. World Journal of Pharmacy and Pharmaceutical Sciences
QUALITY BY DESIGN (QbD) APPROACH TO DEVELOPMENT OF
ANALYTICAL RP-HPLC METHOD FOR REGADENOSON AND
BALOFLOXACIN
Parvin I. Shaha*1, Mirza Shahed Baig
2 and Shaikh Sayeed-Ur-Reheman
3
1,2
Y. B. Chavan College of Pharmacy, Dr. Rafiq Zakaria Campus, Rauza Bagh, Aurangabad-
431001.
3Allana College of Pharmacy, Azam Campus, Hidayatulla Road, Pune-411001.
ABSTRACT
Quality by design (QbD) refers to the achievement of certain
predictable quality with desired and predetermined specifications. A
very useful component of the QbD is the understanding of factors and
their interaction effects by a desired set of experiments. The present
study describes the development of a comprehensive science and risk
based RP-HPLC method and subsequent validation for the analysis of
Regadenoson and Balofloxacin using a quality by design approach.
Experimental designs were applied for multivariate optimization of the
experimental conditions of RP-HPLC method. Interaction of
independent factors on the depended factor such as tailing factor was
studied for both drug. Box Behenken Experimental Design was used to study response
surface technique and to study in depth the effects of these independent factors. The
optimized chromatographic conditions of HPLC method for regadenoson were water (0.1%
o-phosphoric acid): methanol (60:40) as mobile phase, flow rate 1.2 ml/min, wavelength 247.
And for Balofloxacin were flow rate 1ml/min, pH 5.7 and Phosphate buffer: Acetonitrile
(70:30) as mobile phase. The optimized method condition was validated according to ICH
guidelines to confirm LOD and LOQ, linearity, accuracy and precision. The proposed method
can be used for routine analysis of Regadenosone and Balofloxacin in quality control
laboratories.
KEYWORDS: Quality by design, Regadenoson, Balofloxacin, HPLC.
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
SJIF Impact Factor 7.421
Volume 7, Issue 11, 1151-1164 Research Article ISSN 2278 – 4357
*Corresponding Author
Parvin I. Shaha
Y. B. Chavan College of
Pharmacy, Dr. Rafiq Zakaria
Campus, Rauza Bagh,
Aurangabad-431001.
Article Received on
31 August 2018,
Revised on 21 Sept. 2018,
Accepted on 12 Oct. 2018,
DOI: 10.20959/wjpps201811-12581
www.wjpps.com Vol 7, Issue 11, 2018.
1152
Shaha et al. World Journal of Pharmacy and Pharmaceutical Sciences
1. INTRODUCTION
Chemically regadenoson (REGA) is 1-[6-amino-9-[(2R,3R,4S,5R)-3,4 dihydroxy-5
(hydroxymethyl) oxolan-2-yl] purin-2-yl]-N-methylpyrazole-4-carboxamide. REGA is an
adenosine derivative and selective A2A adenosine receptor agonist with coronary
vasodilating activity. It is used as Coronary Vasodilator, Pharmacologic Stress Agent.
whereas Balofloxacin (BALO) is Chemically1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-
7-(3-methyl amino) piperidin-1-yl)-4-oxoquinoline-3-carboxylic acid. BALO is used as
antibacterial. The bactericidal action of BALO results from interference with the enzyme
DNA gyrase (Topoisomerase II & IV enzyme) which is required for the synthesis of bacterial
DNA. Balofloxacin is effective against Gram-negative bacteria.
N
NN
N
NH2
O
OHOH
HO
N
N
O
HN CH3
Figure 1: Chemical structure of REGA.
N
HN
N
F
O
OH
O
O
Figure 2: Chemical Structure of Balofloxacin.
2. MATERIAL AND METHOD
2.1.Reagent and chemicals
A pure drug sample of REGA was obtained as gift sample from Wokhhradt pharmaceutical
Ltd, Aurangabad (India). And drug sample of BALO was obtained as gift sample from Lupin
pharmaceutical, Aurangabad(India). All chemicals used were HPLC grade purchased from E.
www.wjpps.com Vol 7, Issue 11, 2018.
1153
Shaha et al. World Journal of Pharmacy and Pharmaceutical Sciences
Merck, Mumbai (India). All aqueous solutions were prepared with HPLC grade water
obtained in- house, Milli Q water purification system.
2.2.Instrument and software
HPLC analysis was carried out using a Jasco HPLC 2080 model chromatograph (Japan)with
a PU-2080 isocratic delivery system (pump), Jasco UV-2075 plus detector, the analytical
column used is Grace reverse phase C-18 column (4.6 × 250 mm, 5 μm particle size). Data
acquisition and processing was obtained using JASCO BORWIN software. The wavelength
of maximum absorbance was detected by UV-Visible spectrophotometer (Double Beam),
Shimadzu UV 1800 model and wavelength scanning range 200-400nm was exercised using
UV probe software. For applying QbD software used was Design of expert® version 10.0.2.
2.3. Preparation of standard stock solution
Standard stock solution of REGA and BALO for optimization of experiments was prepared
separately by accurately weighing 10mg of drug and dissolving in 100ml Methanol to get a
final concentration of 100µg/ml. From above stock solution further dilutions was made to
prepare 10µg/ml for analysis.
2.4. Preparation of mobile phase
Mobile phase for REGA was prepared by mixing of 60ml of Water containing 0.1% o-
phosphoric acid and 40ml of Methanol then sonicate it for 30 minutes and vaccume filter
through 0.45μ Millipore filter. Phosphate buffer prepared by dissolving 1gm of potassium
dihydrogen ortho phosphate in 500ml HPLC grade water and pH was adjusted to 5.5 by o-
phosphoric acid. For BALO mobile phase was prepared by mixing 70ml phosphate buffer
with 30 ml Acetonitrile then sonicated for 30min and vaccume filter through 0.45μ Millipore
filter.
2.5. Selection of wavelength for analysis
Appropriate dilution of standard solution of REGA and BALO were prepared separately by
using methanol and it was scanned in UV spectrophotometer for entire wavelength region
200-400 nm in spectrum mode for maximum absorbance. The wavelength of maximum
absorbance for REGA and BALO was selected as 247nm and 293 respectively.
www.wjpps.com Vol 7, Issue 11, 2018.
1154
Shaha et al. World Journal of Pharmacy and Pharmaceutical Sciences
2.6. Analytical target profile
QbD is systematic approach to product, process design and development. Hence it begins
with determination of goal or method intent. An emphasis is given on the product and process
understanding. Here method intent was to develop HPLC method for REGA and BALO
which is robust, accurate, precise and USP tailing less than 1.25 and 1.2 respectively. number
of theoretical plates as per requirement and short analysis time i.e. less than 10 min. as per
QbD norms a robust method should be developed with help of visualized a design space.
2.7. Initial Chromatographic condition
For REGA Chromatographic separation was carried on Grace C-18 column (4.6×250 mm, 5-
µm particle size) by using Water (0.1%o-phosphoric acid):methanol (60:40) as mobile phase
and Peak was obtained at 247nm with retention time of 4.3 min at flow rate of 1.1 ml/min. for
BALO separation was carried out using Phosphate buffer (pH 5.5): Acetonitrile (70:30) as
mobile phase. Peak was obtained at 293nm with retention time of 2.4 min at flow rate of 1
ml/min, prior to the injection of drug solution column was equilibrated with mobile phase.
Further changes were done according to optimization model.
2.8. Critical Quality Attribute (CQA)
By screening critical factors which affect the tailing were determined. Factor such as flow
rate, pH , wavelength, methanol and Acetonitrile concentration in mobile phase were found to
be critical. Selection of stationary phase was also critical parameter.
2.9. Design of Experiment (DoE)
Optimization was done by response surface methodology, applying a three level Box
Behnken design with three centre points (Table 1.).
Table 1: Chromatographic Factors and Response Variables For Box Behnken
Experimental Design.
Drug Sr.No. Chromatographic Condition
Low Level used
Centre High
REGA
1. Flow rate (X1) 1 1.1 1.2
2. Methanol.(X2) 30 40 50
3. Wavelength (X3) 245 247 249
BALO
1 Flow rate (X1) 0.8 1 1.2
2 pH (X3) 5 5.5 6
3 Acetonitrile (X2) 20 30 40
www.wjpps.com Vol 7, Issue 11, 2018.
1155
Shaha et al. World Journal of Pharmacy and Pharmaceutical Sciences
Three factor for REGA such as flow rate, wavelength and methanol concentration in mobile
phase were selected as independent variables and in case of BALO independed factor
selected was flow rate, pH and Acetonitrile concentration in mobile phase. USP tailing were
selected as dependent variables. The resulting data were fitted into Design Expert® software
and analysed statistically using analysis of variance (ANOVA). The data were also subjected
to 3-D response surface methodology to determine the influence of independed on dependent
variables. The probable trial runs using Box behnken designs are as shown in Table 2.
Application of multivariate regression analysis resulted in a fitted full quadrate mode for the
average responses for USP peak tailing given by the equation 1.
Y= β0+β1X1+β2X2+ β3X3+ β11X12+ β22X2
2+ β33 X3
2 + β12 X1 X2+ β13 X1X3+ β23X2X3.
Where Y is the response, β0 is the arithmetic mean response. β1 β2 and β3 are regression
coefficients of the factor X1, X2 and X3 respectively. β11, β22 β33 are squared coefficients β12,
β13 and β23 are interaction coefficients.
Table 2: Box Behnken method used for REGA and BALO in HPLC method for
optimization.
Run
REGA BALO
Coded
(X 1,X2, X3)
Flow Rate
(ml/min)
Wavelength
(nm)
Methanol
Conc.(%)
Flow Rate
(ml/min) pH
Acetonitrile
Conc. (%)
1. +0+ 1.2 247 50 1.2 5.5 40
2. -0+ 1 247 50 0.8 5.5 40
3. 000 1 247 40 1 5.5 30
4. 000 1 247 40 1 5.5 30
5. ++0 1.2 .249 40 1.2 6 30
6. 0++ 1.1 249 50 1 6 40
7. -0- 1 247 30 0.8 5.5 20
8. +0- 1.2 247 30 1.2 5.5 20
9. 0+- 1.1 249 30 1 6 20
10. +-0 1.2 245 40 1.2 5 30
11. 000 1.1 247 40 1 5.5 30
12. -+0 1 249 40 0.8 6 30
13. 0-+ 1.1 245 50 1 5 40
14. 000 1.1 247 40 1 5.5 30
15. --0 1 245 40 0.8 5 20
16. 0-- 1.1 245 30 1 5 20
17. 000 1.1 247 40 1 5.5 30
www.wjpps.com Vol 7, Issue 11, 2018.
1156
Shaha et al. World Journal of Pharmacy and Pharmaceutical Sciences
2.10. Method Validation
a. Linearity
Standard calibration curves was prepared saparatly with five different conc. of REGA and
BALO by making serial volume to volume dilution of stock solution with methanol, over the
range of 5,10,15,20,25 µg/ml. Linear concentration curves of peak area versus drug
concentration were plotted using linear least squares regression and evaluated for linearity.
b. Accuracy
Accuracy was obtained by performing recovery studies by the standard addition method at
different levels of standard drug i.e., 80%, 100% and 120% of REGA and BALO to
previously analyzed tablet powder sample and mixtures were reanalyzed by the proposed
method. From the amount of drug found percentage recovery was calculated.
c. Precision
Precision of the method was performed by intra-day and inter-day studies. For intra-day
studies, triplicate of prepared samples were analyzed within same day. For inter -day
validation, same concentrations were determined on three separate days. The % RSD values
obtained from peak area should be less than 2.
d. Limits of Detection and Limit of Quantification
LOD and LOQ were estimated experimentally and mathematically using formulae:
LOD = 3.3 standard deviation of Y intercept/ slope of the calibration curve.
LOQ = 10 standard deviation of y intercept/slope of the calibration curve.
LOD and LOQ values were experimentally verified by diluting known concentrations of
sample solution.
e. Robustness
Robustness of the method was determined by carrying out the analysis under conditions
during which flow rate (±0.1ml/min), Wavelength (±0.1 units), mobile phase composition,
were altered and the effects on the area were noted.
3. RESULT AND DISCUSSION
3.1. Method Design
Analysis of variance(ANOVA) was perform for findings are ‘statistically significant’ by
convention, it is p<0.05.A value of Probe > F was found to be less than 0.05. Entire model
www.wjpps.com Vol 7, Issue 11, 2018.
1157
Shaha et al. World Journal of Pharmacy and Pharmaceutical Sciences
was fitted well for optimization. A Significant factors found for REGA were flow rate (p-
value= 0.0001), methanol concentration (p-value=<0.0001), interaction of flow rate x flow
rate (p-value= 0.0034), interaction of wavelength x wavelength (p-value= 0.0035), methanol
concentration x methanol concentration (p-value=<0.0063) and interaction of flow rate x
methanol conc. (p-value= 0002).Significant factors found for BALO was flow rate (p-value=
0.0003), pH (p-value= <0.0001), interaction pH x pH (p-value= 0.0001), interaction of ACN
conc. x ACN conc. (p-value= 0.0045), flow rate x ACN conc. (p-value=0.0020), interaction
of flow rate x pH (p-value= 0.0416) and interaction of ACN conc. x pH (p-value= <0.0001).
Regression analysis and p-values obtained from software generated report for REGA and
BALO are given in Table 3 and Table 4 respectively.
Table 3: Regression coefficients and associated probability values (p-values) for USP
tailing of REGA.
Table 4: Regression coefficients and associated probability values (p-values) for USP
tailing of BALO.
Sr no. Term Coefficient p-value
1 Intercept 1.24 <0.0001
2 flow rate(A) -0.11 0.0001
3 Wavelength(B) 0.018 0.1766
4 methanol conc.(C) 0.091 <0.0001
5 flow rate x wavelength(AB) 0.03 0.7703
6 flow rate x methanol conc.(AC) 0.12 0.0002
7 wavelength x methanol conc.(BC) -0.015 0.3927
8 flow rate x flow rate(A2) 0.042 0.0034
9 wavelength x wavelength(B2) 0.069 0.0035
10 methanol conc. x methanol conc.(C2) 0.062 0.0063
Sr no. Term Coefficient p-value
1. Intercept 1.21 0.0001
2. flow rate(A) -0.046 0.0003
3. pH(B) -0.090 < 0.0001
4. methanol conc.(C) 3.750 0.7352
5. flow rate x pH(AB) 0.038 0.0416
6. flow rate x ACN conc.(AC) 0.004 0.0020
7. pH xACN conc.(BC) 0.14 < 0.0001
8. flow rate x flow rate(A2) 0.031 0.0727
9. pH x pH (B2) -0.11 0.0001
10. ACN conc. x ACN conc.(C2) 0.036 0.0045
www.wjpps.com Vol 7, Issue 11, 2018.
1158
Shaha et al. World Journal of Pharmacy and Pharmaceutical Sciences
3.2. Response surface plot
Response surface and contour plot were studied to visualize effect of factor and their
interaction so as to get optimized method. In case of REGA, At constant methanol conc. 40%
it can be observed that between wavelength 248-249nm tailing was found to be more than
1.25, tailing was in specified limit below 247nm (Fig.3). At constant wavelength 247nm
methanol conc. is not showing much effect but when flow rate decreases result in increases in
peak tailing above 1.25 (Fig.4). At constant flow rate 1.1ml/min wavelength around 249nm
and methanol conc. at 45-50% tailing factor exceeded the limit (Fig.5).
In case of BALO, At constant ACN conc. at 30% it was found that when pH in range of 5.4-
5.6 tailing was more than 1.2 and tailing was in specified limit at higher pH 5.7-5.9. Flow rate
is not showing much effect but when flow rate decreased throughout pH range tailing was
increases (Fig.6). At constant pH 5.7 when ACN conc. not showing much effect but when
flow rate decreases’ results in higher peak tailing (Fig.7). At constant flow rate at 1ml/min it
was found that at ACN conc. around 25% and pH between 5.4 -5.6 tailing factor exceeded
the limit hence at higher ACN conc. response was optimum though pH is varied (Fig.8).
Design-Expert® SoftwareFactor Coding: ActualUSP tailing ( )
Design points above predicted valueDesign points below predicted value1.48
1.02
X1 = A: flow rateX2 = B: wavelenght
Actual FactorC: methanol conc. = 40
245
246
247
248
249
1
1.05
1.1
1.15
1.2
1
1.1
1.2
1.3
1.4
1.5
US
P t
ailin
g (
)
A: flow rate (ml/imn)
B: wavelenght (nm)
Fig. 3: 3D Response Plot of tailing factor against flow rate and wavelength.
www.wjpps.com Vol 7, Issue 11, 2018.
1159
Shaha et al. World Journal of Pharmacy and Pharmaceutical Sciences
Design-Expert® SoftwareFactor Coding: ActualUSP tailing ( )
Design points above predicted valueDesign points below predicted value1.48
1.02
X1 = A: flow rateX2 = C: methanol conc.
Actual FactorB: wavelenght = 247
30
35
40
45
50
1
1.05
1.1
1.15
1.2
1
1.1
1.2
1.3
1.4
1.5
US
P t
ailin
g (
)
A: flow rate (ml/imn)C: methanol conc. (ml)
Fig. 4: 3D Response Plot of tailing factor against flow rate and methanol conc.
Design-Expert® SoftwareFactor Coding: ActualUSP tailing ( )
Design points above predicted valueDesign points below predicted value1.48
1.02
X1 = B: wavelenghtX2 = C: methanol conc.
Actual FactorA: flow rate = 1.1
30
35
40
45
50
245 246
247 248
249
1
1.1
1.2
1.3
1.4
1.5
US
P t
ailin
g (
)
B: wavelenght (nm)C: methanol conc. (ml)
Fig. 5: 3D Response Plot of tailing factor against wavelength and methanol conc.
Design-Expert® SoftwareFactor Coding: Actualtailing
Design points above predicted valueDesign points below predicted value1.4
1
X1 = A: flow rateX2 = B: pH
Actual FactorC: ACN conc. = 30
5.4
5.5
5.6
5.7
5.8
5.9
6
0.8
0.9
1
1.1
1.2
0.8
0.9
1
1.1
1.2
1.3
1.4
taili
ng
A: flow rate (ml/min)
B: pH
Fig. 6: 3D Response Plot of tailing factor against flow rate and pH.
www.wjpps.com Vol 7, Issue 11, 2018.
1160
Shaha et al. World Journal of Pharmacy and Pharmaceutical Sciences
Design-Expert® SoftwareFactor Coding: Actualtailing
Design points above predicted valueDesign points below predicted value1.4
1
tailing = 1.24Std # 16 Run # 14X1 = A: flow rate = 1X2 = C: ACN conc. = 30
Actual FactorB: pH = 5.7
20
25
30
35
40
0.8
0.9
1
1.1
1.2
0.8
0.9
1
1.1
1.2
1.3
1.4
taili
ng
A: flow rate (ml/min)C: ACN conc. (ml)
Fig. 7: 3D Response Plot of tailing factor against flow rate and ACN conc.
Design-Expert® SoftwareFactor Coding: Actualtailing
Design points above predicted valueDesign points below predicted value1.4
1
X1 = B: pHX2 = C: ACN conc.
Actual FactorA: flow rate = 1
20
25
30
35
40
5.4 5.5
5.6 5.7
5.8 5.9
6
0.8
0.9
1
1.1
1.2
1.3
1.4
taili
ng
B: pH
C: ACN conc. (ml)
Fig. 8: 3D Response Plot of tailing factor against pH and ACN conc.
3.3. Optimized Method
To obtain optimum set of condition to achieve desired goal composite desirability parameters
were applied. For REGA and BALO Response was set to minimum tailing below target value
of 1.25 and 1.2 respectively. Optimum condition having desirability was chosen from
obtained runs. The optimized condition for REGA was found to be flow rate of 1.2 ml/min,
Methanol concentration of 40% and wavelength at 247 nm which give sharp peak at retention
time 4.1 min (Fig.9). And for BALO flow rate of 1 ml/min, ACN concentration of 40% and
pH 5.7 which give sharp peak at retention time 2.1 min (Fig.10).
www.wjpps.com Vol 7, Issue 11, 2018.
1161
Shaha et al. World Journal of Pharmacy and Pharmaceutical Sciences
Fig. 9: HPLC Chromatogram of REGA.
Fig. 10: HPLC Chromatogram of BALO.
3.4. Control strategy
Set of conditions were analyzed to compare predicted response with actual response. Six
Replicate of 20µg/ml of solution at above specified conditions were taken. Difference in the
response was not more than 3%.
www.wjpps.com Vol 7, Issue 11, 2018.
1162
Shaha et al. World Journal of Pharmacy and Pharmaceutical Sciences
Table no. 5: validation study for REGA and BALO.
Sr.no Parameter Data for REGA Data for BALO
1. Linearity 5-25 µg/Ml 5-25 µg/Ml
2. Regressions equation y = 99125x – 25985 y = 23556x – 8212
3. Correlation coefficient (r2) 0.999 0.999
4. Retention time (mins) 4.1 2.1
5.
Accuracy
80 %
100 %
120 %
99.30
98.75
99.94
99.40
99.43
101.1
6. LOD(µg/mL) 1.13 8.3
7. LOQ(µg/mL) 3.44 7.1
8.
Precision (RSD, %)
Intraday (n=3)
Interday (n=3)
1.43%
1.36%
1.24
1.66
9. Robustness Robust Robust
4. CONCLUSION
A systematic and practical approach was utilized to develop an efficient and robust HPLC
method for RAGA and BALO. The application of quality by design resulted in a
methodology that was simple in implementation, chromatographically efficient. Multivariate
regression analysis was successfully employed to effectively screen the main effects of
factors that significantly affected the resolution and tailing. Three factors for REGA and
BALO were determined to significantly affect the peaks were then analyzed to determine
their interactions and quadratic effects with the least number of runs as possible using a Box–
Behnken design in conjunction with response surface methodology. A desirability function
was applied to determine the optimum conditions. The optimum conditions were validated
according to ICH Q2R1 guidelines.
5. REFERENCES
1. Mittu, A.C. B.; Chauhan, P. Analytical Method Development and Validation: A Concise
Review. Journal of Analytical & Bioanalytical Techniques 2015; 6: 75-76.
2. ICH Harmonised tripartite guideline pharmaceutical development Q8
(R2).http://www.ichorg. (accessed on feb 2,16).
3. ICH Harmonised tripartite guideline pharmaceutical quality system Q10.
http://www.ich.org (accessed feb 12,15.)
4. ICH Harmonised tripartite guideline quality risk management Q9. http://www.ich.org.
(accessed feb 12,15.)
www.wjpps.com Vol 7, Issue 11, 2018.
1163
Shaha et al. World Journal of Pharmacy and Pharmaceutical Sciences
5. Jadhav, M.L.; Tambe, S.R. Analytical approach on quality by design. International
Journal of chromatography research, 2013; 4: 1724-1726.
6. Yadav, N. K.; Raghuvanshi, A.; Sharma, G.; Beg, S.; Katare, O. P.; Nanda, S. QbD-
Based Development and Validation of a Stability-Indicating HPLC Method for
Estimating Ketoprofen in Bulk Drug and Proniosomal Vesicular System. Journal of
Chromatographic Science, 2015; 5-6.
7. Borman, P.; Nethercote, P.; Chatfield, M.; Thompson, D.; Truman K. The Application of
Quality by Design to Analytical Methods. Journal of Pharma Tech research, 2007;
31(12): 142-152.
8. Schweitzer, M.; Pohl, M.; Hanna-Brown, M.; Nethercote, P.; Borman, P.; Hansen, G.;
Smith, K.; Larew J. Implications and Opportunities of Applying QbD Principles to
Analytical Measurements. Journal of Pharma Techresearch, 2010; 34(2): 52-59.
9. Awotwe-Otoo, D.; Agarabi, C.; Faustino, P.J.; Habib, M.J.; Lee, S.; Khan, M.A.; Shah,
R.B.; Application of Quality by Design elements for the development and optimization of
an analytical method for protamine sulphate. Journal of Pharmaceutical and Biomedical
Analysis, 2012; 25: 61-67.
10. Gopani, M.; Patel, R. B.; Patel, M. R.; Solanki, A. B., Development of new high
performance thin layer chromatographyic method for quantitative estimation of lamivudin
and zidovudin combine tablet dosage form using quality by design approach . Journal of
Liquid Chromatography & Related Technologies, 2014; 37(17): 2420–2432.
11. Hammad, F.S.; Fatatry, M.A.; Habib, A.; Badran, A.I. Development And Validation Of
Quality By Design Optimized Reversed Phase HPLC Method For Simultaneous
Estimation Of Telmisartan And Amlodipine. International Journal of Biological &
Pharmaceutical Research, 2013; 4(10): 697-701.
12. Jadhav, M. L.; Tambe, S. R. Implementation Of QbD Approach to the Analytical Method
Development and Validation for the Estimation of Propafenone Hydrochloride in Tablet
Dosage Form. International journal of Chromatography Research, 2013; 1–9.
13. Khurana, R. K.; Rao, S.; Beg, S.; Katare, O.; Singh, B. Systematic Development and
Validation of a Thin-Layer Densitometric Bioanalytical Method for Estimation of
Mangiferin Employing Analytical Quality by Design Approach. Journal of
Chromatographic Science, 2016; 54(5): 829–841.
14. Bhatt, D.A.; Rane, S.I. QbD approach to analytical RPHPLC method development and its
validation. International Journal of Pharmaceutical Science, 2011; 3: 179-187.
www.wjpps.com Vol 7, Issue 11, 2018.
1164
Shaha et al. World Journal of Pharmacy and Pharmaceutical Sciences
15. Sangshetti, J.N.; Ahmed, R.Z.; Zaheer, Z. Use of Systematic Approach for Development
of RP-HPLC Method for Simultaneous Determination Of Lopinavir and Ritonavir.
Journal OfAnalytical Chemistry Letters, 2014; 4: 123-131.
16. Punam, M. Development and Validation of Analytical method for estimation of
Balofloxacin in Bulk and Pharmaceutical dosage form. International Journal of Pharm
Tech Research, 2011; 3(4): 1-5.
17. Malathi, S.; Sivakumar, T. Development and validation of HPTLC method for
balofloxacin in bulk and its tablet dosage form. Internatinal Journal of PharmTech
Research, 2014; 6: 392-395.
18. Kaminski L, Degenhardt M, Ermer J, Feubner C, Fritzn H, Peter L, Bernd R, Martin T,
Hermann W. Efficient and economic HPLC performance qualification. Journal of
Pharmaceutical and Biomedical Analysis, 2010; 51: 557-564.
19. Sethi, P. D. Quantitative Analysis of Pharmaceutical Formulations. high performance
liquid chromatography: quantitative analysis of pharmaceutical formulations; CBS
Publishers & Distributors: New Delhi, India, 2008; 14-30.
20. Chatwal, G.R.; Anand, S.K. high performance liquid chromatography. Instrumental
methods of chemical analysis, 5th edition, Mumbai:Himalaya Publishing House, 2007; 2:
624-2.639.